Oral ivermectin for treatment of pediculosis capitis

Pediatric Infectious Disease Journal

Volumn 29, Issue 11, 2010, Pages 991-993

  Ameen, Mahreen ^a   Arenas, Roberto ^b   Villanueva Reyes, Janeth ^b   Ruiz Esmenjaud, Julieta ^b   Millar, Daniel ^c   Domínguez Dueñas, Francisca ^d   Haddad Angulo, Alexandra ^b   Rodríguez Álvarez, Mauricio ^e  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Research and Development of Viral Vaccines   (Mexico)

^e Laboratorio de Biológicos y Reactivos de México   (Mexico)

Author keywords

Ivermectin; nit; parasite; pediculosis capitis

Indexed keywords

IVERMECTIN;

ADOLESCENT; APPLICATION SITE EXCORIATION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOUSE; MALE; PEDICULOSIS CAPITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; SINGLE DRUG DOSE; SKIN EXAMINATION; TREATMENT DURATION;

EID: 78149273691     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181e63f5f     Document Type: Article

References (30)

1. Brogdon W, McAllister J. Insecticide resistance and vector control. Emerg Infect Dis. 1998;4:605-613.
2. Burkhart CG, Burkhart CN. Clinical evidence of lice resistance to overthe-counter products. J Cutan Med Surg. 2000;4:199-201.
3. Kaul N, Palma KG, Silagy SS, et al. North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz). J Cutan Med Surg. 2007;11:161-167.
4. Meinking TL, Villar ME, Vicaria M, et al. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfiatm): a safe and effective topical treatment for head lice (Pediculosis humanus capitis). Pediatr Dermatol. 2010;27:19-24.
5. Glaziou P, Nyguyen LN, Moulia-Pelat JP, et al. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol. 1994;45:253-254.
6. Youssef MY, Sadaka HA, Eissa MM, et al. Topical application of ivermectin for human ectoparasites. Am J Trop Med Hyg. 1995;53:652-653.
7. Foucault C, Ranque S, Badiaga S, et al. Oral ivermectin in the treatment of body lice. J Infect Dis. 2006;193:474-476.
8. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents. 2008;31:91-98.
9. Ranson H, Jensen B, Vulule JM, et al. Identification of a point mutation in the voltage-gated sodium channel gene of Kenyan Anopheles gambiae associated with resistance to DDT and pyrethroids. Insect Mol Biol. 2000;9:491-497.
10. Bennett DG. Clinical pharmacology of ivermectin. J Am Vet Med Assoc. 1986;189:100-104.
11. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
12. Meinking TL, Entzel P, Villar ME, et al. Comparative efficacy of treatments for Pediculosis capitis infestations: update 2000. Arch Dermatol. 2001;137:287-292.
13. Hansen RC, O'Haver J. Economic considerations associated with Pediculus humanus capitis infestation. Clin Pediatr (Phila). 2004;43:523-527.
14. Nordt SP, Chew G. Acute lindane poisoning in three children. J Emerg Med. 2000;18:51-53.
15. Jones KN, English JC III. Review of common therapeutic options in the United States for the treatment of Pediculosis capitis. Clin Infect Dis. 2003;36:1355-1361.
16. Downs AM, Stafford KA, Harvey I, et al. Evidence for double resistance to permethrin and malathion in head lice. Br J Dermatol. 1999;141:508-511.
17. Meinking TL. Clinical update on resistance and treatment of Pediculosis capitis. Am J Manag Care. 2004;10:S264-S268.
18. González Audino P, Barrios S, Vassena C, et al. Increased monooxygenase activity associated with resistance to permethrin in Pediculus humanus capitis (Anoplura: Pediculidae) from Argentina. J Med Entomol. 2005;42:342-345.
19. Ko CJ, Elston DM. Pediculosis. J Am Acad Dermatol. 2004;50:1-12.
20. Kristensen M, Knorr M, Rasmussen AM, et al. Survey of permethrin and malathion resistance in human head lice populations from Denmark. J Med Entomol. 2006;43:533-538.
21. Akisu C, Delibas SB, Aksoy U. Albendazole: single or combination therapy with permethrin against Pediculosis capitis. Pediatr Dermatol. 2006;23:179-182.
22. Namazi MR. Levamisole: a safe and economical weapon against pediculosis. Int J Dermatol. 2001;40:292-294.
23. Hipolito RB, Mallorca FG, Zuniga-Macaraig ZO, et al. Head lice infestation: single drug versus combination therapy with one percent permethrin and trimethoprim/sulfamethoxazole. Pediatrics. 2001;107:E30.
24. Sim S, Lee IY, Lee KJ, et al. A survey on head lice infestation in Korea (2001) and the therapeutic efficacy of oral trimethoprim/sulfamethoxazole adding to lindane shampoo. Korean J Parasitol. 2003;41:57-61.
25. Cestari SC, Petri V, Rotta O, et al. Oral treatment of crusted scabies with ivermectin: report of two cases. Pediatr Dermatol. 2000;17:410-414.
26. del Mar. Saez-De-Ocariz M, McKinster CD, Orozco-Covarrubias L, et al. Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin. Clin Exp Dermatol. 2002;27:264-267.
27. Amazigo U. The African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2008;102(suppl 1):19-22.
28. Strycharz JP, Yoon KS, Clark JM. A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae). J Med Entomol. 2008;45:75-81.
29. Strong M, Johnstone PW. Interventions for treating scabies. Cochrane Database Syst Rev. 2007: CD000320.
30. Lebwohl M, Clark L, Levitt J. Therapy for head lice based on life cycle, resistance, and safety considerations. Pediatrics. 2007;119:965-974.